Form D · Biotechnology
OncoMyx Therapeutics, Inc.
Phoenix, AZ · CIK 0001779436
Offering snapshot reported Dec 13, 2021 · SEC filing
- Reported sold
- $50M Offering amount: $50M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 19, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 13, 2021 | Initial | $50,000,000 | No comparison | 13 | SEC filing |
| Jun 18, 2019 | Initial | $8,000,001 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-424596
Source: Form D, filed Dec 13, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Charles M. Baum, M.D., Ph.D. | Director |
| Kanad Das, Ph.D. | Director |
| Douglas Grant Mc Fadden, Ph.D. | Director |
| Widya Mulyasasmita, Ph.D. | Director |
| Steven J. Potts, Ph.D. | Director, Executive |
| Benjamin Rovinski, Ph.D. | Director |
| Jason Rushton | Director |
| Leslie Sharp, Ph.D. | Executive |
| Michael G. Wood | Executive |
| Ting Xiao | Director |
| Ting Xiao, C.F.A., F.R.M. | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
850 N. 5th St., Ste. 402
Phoenix, AZ, 85004
Phoenix, AZ, 85004